Dear colleagues, Members of GOLD committees,

This letter arises from discussions and correspondence between colleagues involved in respiratory research or the diagnosis and treatment of lung diseases, as well as from a review of the literature on COPD. As discussed below, it is written in the hope that we can persuade members of the GOLD committee to change the method by which mild airway obstruction is defined by the GOLD guidelines.

We very much welcome the continued efforts of the GOLD group to stimulate interest and awareness of the high prevalence of COPD, its morbidity, effects on quality of life and on mortality. There is no doubt that COPD is a major public health problem of which the public, health workers and health authorities were insufficiently aware. It is therefore an important achievement that WHO, ERS, ATS, APSR, ALAT and WONCA and many distinguished individuals have joined forces to increase awareness about the burden of disease, by publishing reports and guidelines for diagnostic procedures and interventions which have been adopted by numerous international and national organisations.

However, there is one area which has given rise to continuous published criticism: the criterion for confirming airway obstruction. It is well known that the FEV_1/FVC ratio declines with increasing age and height, even in healthy lifelong non-smokers, in whom the lower limit of normal drops below a ratio of 0.7 from about 45 years of age [1-6]. It has been shown [4-27] that using the fixed ratio causes up to 50% over-diagnosis (misclassification) above that age. Adult smokers suspected of having COPD are not at increased risk of respiratory symptoms, respiratory morbidity, or all-cause mortality until the ratio falls below the age-corrected fifth percentile lower limit of the normal range [26, 28].

The present GOLD guidelines on the spirometric assessment of airway obstruction are scientifically untenable [1, 29-31] and have given rise to editorials in *Chest* [32], the *European Respiratory Journal* [17], the *American Journal of Respiratory and Critical Care Medicine* [33], *COPD: Journal of Chronic Obstructive Pulmonary Disease* [34], and *Respiratory Care* [35], with a plea for revision. The very significant over-diagnosis in elderly subjects due to this guideline is akin to selling sickness. There is considerable psychological impact, and there are wider health consequences of incorrectly being labeled as having COPD, a syndrome associated with a poor prognosis with regard to morbidity, quality of life and mortality and therefore a psychological burden for the subject, his family and wider environment. Subjects erroneously labeled become a target for individual and lifelong interventions which are associated with side effects. This is all the more unacceptable since evidence for the long term effectiveness of treatment of mild COPD, apart from smoking cessation, is lacking [28, 36]. Erroneous interventions also constitute an unnecessary financial burden for society.

We applaud the GOLD committee for raising interest in COPD research. However, over-diagnosis will lead to the inclusion of subjects who do not have COPD into the research pool, thereby adding noise to any signals that researchers are looking for when trying to unravel the causes of COPD and hence find potential treatments. Also problematic is excluding younger subjects who may have airway obstruction (false negatives) when the fixed ratio is used [4-5, 10, 16, 18, 21, 37-40]. For research purposes, it is far better to limit recruitment to subjects who definitely have the disease, but this urgently requires adjustment of the present guideline on a fixed FEV_1/FVC ratio.

We appreciate the consequences of changing course when so many societies and organisations will be affected by replacing the fixed ratio by the lower limit of normal, and more importantly general practitioners and clinicians may have to review and revise previous diagnoses. However, in the light of new evidence it is never too late to change a decision made in good faith. We are therefore appealing to you, members of the GOLD committee, to change the method by which mild airway obstruction is defined by the GOLD guidelines in order to abandon the fixed ratio forever in favour of the lower limit of normal.

Sincerely yours,

The Pulmonaria Group

Philip H Quanjer, MD, PhD, Department of Pulmonary Diseases and Department of Paediatrics, Erasmus Medical Centre, Erasmus University, Rotterdam, The Netherlands.
Paul L Enright, MD, PhD, College of Public Health, The University of Arizona, Tucson, AZ, USA.
Martin R Miller, MD, PhD, Department of Medicine, University Hospital Birmingham NHS Trust, Birmingham B29 6JD, UK.
Janet Stocks, PhD, Portex Respiratory Unit, UCL, Institute of Child Health, London, UK.
Gregg Ruppel, RRT, RPFT, Pulmonary Function Laboratory, Saint Louis University Hospital, St. Louis MO, USA.
Maureen P Swanney, PhD, Respiratory Physiology Laboratory, Christchurch Hospital, Canterbury District Health Board, Christchurch, New Zealand.
Robert O Crapo, Pulmonary Division, LDS Hospital and University of Utah, Salt Lake City, Utah, USA
Ole F Pedersen, MD, DMSc, Institute of Public Health, Department of Environmental and Occupational Medicine, University of Aarhus, Aarhus, Denmark.
Emanuela Falaschetti, MSc, Department of Epidemiology and Public Health, University College London, London, UK.
Jan P Schouten, PhD, Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Robert L. Jensen, MD, PhD, Pulmonary Division, LDS Hospital and University of Utah, Salt Lake City, Utah, USA

Organisations

ANZSRS: Australian and New Zealand Society of Respiratory Science
ARTP: Association for Respiratory Technology and Physiology
CAHAG: COPD & Astma Huisartsen Advies Groep (COPD & Asthma GP Advisory Group)
SKL: Dutch Paediatric Repiratory Society
Education for Health, Warwick, UK
National Respiratory Training Center, Virginia, US
NHG: Nederlands Huisartsen Genootschap (Dutch Society of GPs)
NVALT: Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (Dutch Thoracic Society)
NVLA: Nederlandse Vereniging Longfunctie Analisten (Dutch Society of Respiratory Technicians)
PCRS - UK: Primary Care Respiratory Society UK
SPLF : Société de Pneumologie de Langue Française
SSMG : Société Scientifique de Médecine Générale
WONCA: World Organization of Family Doctors

Individuals

Shawn Aaron, MD, Ottawa, Ontario, Canada
Peymané Adab, MB ChB, MPH, FFPH, FHKCCM, MD, Birmingham, UK
Sunil Kumar Agarwal MD, MPH, PhD, Raleigh-Durham, NC, USA
Ashutosh N. Aggarwal, MD, Chandigarh, India
Omar A. Al-Rawas, MD, Muscat, Sultanate of Oman
Santiago C. Arce, MD, Buenos Aires, Argentina
Bert G.M. Arets, MD, PhD, Utrecht, the Netherlands
Björn Bake, MD, PhD, Göteborg, Sweden
Lutz Beckert, MB BS, MD, MRCP, FRACP, Christchurch, New Zealand
Helmi Ben Saad, MD, PhD, Sousse, Tunisia
Norbert Berend, Sydney, Australia
Jan Willem van den Berg, MD, Zwolle, the Netherlands
Erik Berglund, MD, PhD, Gothenburg, Sweden
Francesco Blasi, MD, Milan, Italy
Marcel Bonay, MD, PhD, Paris, France
Piotr W. Boros, MD, PhD, Warsaw, Poland
Otto Brändli, MD, Wald, Switzerland
Pierre-Olivier Bridevaux, MD, MSc, Geneva, Switzerland
Peter J. Briffa, BAppSc, GradDipNatRes, GradCertRespSc, MHltSc, CRFS, Camperdown, Australia
Ben Brockway, MD, Dunedin, New Zealand
Michael Brown, CRFS, Brisbane, QLD, Australia
Martyn Bucknall, London, UK
Johan Buffels, MD, PhD, Leuven, Belgium
Felip Burgos Rincón, RPFT, RN, Barcelona, Spain
Debbie Burton, BSc Hons, PhD, Rockhampton, Australia
Joyce Canterbury, RPFT, MEd, MHA, Denver, Colorado, USA
Richard Casaburi, PhD, MD, Torrance, California, USA
Mario Cazzola, MD, Rome, Italy
Stefano Centanni, MD, PhD, Milan, Italy
Isa Cerveri, MD, Pavia, Italy
John Concato, MD, MPH, New Haven, CT, USA
Brendan G. Cooper, Consultant Clin Sci, Birmingham, UK
Ahmet S. Copur, NCHVAMC, North Chicago, USA
Angelo G. Corsico, MD, PhD, Pavia, Italy
John Cotes, MD, PhD, Durham, UK
Derek Cramer, BSc (Hons), MIScT, London, UK
Alan J. Crockett, PSM, MPH, PhD, FANZSRS, Adelaide, Australia
Bruce H. Culver, MD, Seattle, WA, USA
Robert E. Dales, MD, MSc, Ottawa, Ontario, Canada.
Wanchai Dejsomritrutai, MD, Bangkok, Thailand
P.N. Richard Dekhuijzen, MD, PhD, Nijmegen, the Netherlands
Eleonora Del Colle, BAppSci, CRFS, Box Hill, Australia
Helen Dunroy, MD, Dunedin, New Zealand
Derek Figurski, Laboratory Manager, Canberra, Australia
Monica J Fletcher, Warwick, UK
Carlos A. Vaz Fragoso, MD, New Haven, CT, USA
Ashok Fulambarker, MD, FCCP, Chicago Ill, USA
Kevin Gain, PhD, Perth, Australia
Monika Gappa, MD, Wesel, Germany
Margaret W. Gerbase, MD, MSc, PhD, Geneva, Switzerland
John Gibson, BSc MD FRCP, Newcastle upon Tyne, UK
Thomas M. Gill, MD, New Haven, CT, USA
Kim Gooey, Respir Scientist, Frankston, Victoria, Australia
Christopher J. Gore, PhD, Canberra, Australia
Graham Hall, PhD, Perth, Australia
James E. Hansen, MD, Torrance, California, USA
Jon A. Hardie, MD, PhD, Bergen, Norway
John Henderson, MD, Bristol, UK
Eva Hnizdo, PhD, Morgantown, WV, USA
Guy Hollaert, MD, Dottignies, Belgium
Steven Holmes, MD, Shepton Mallet, Somerset, UK
Frederic Hoppin, MD, Pawtucket, RI, USA
Birgitta Houltz, MD, PhD, Gothenburg, Sweden
Bruno Housset, MD, Créteil, France;
Antoinette Houtkooper, BC, Den Helder, the Netherlands
Michael Hughes, DM, FRCP, London, UK
Georg Hülskamp, MD, Münster, Germany
Mark Hurwitz, Director Thoracic Medicine, Canberra, Australia
Robert Hyatt, MD, Rochester, MN, USA
Charles G. Irvin, PhD, Burlington, Vermont, USA
David P. Johns, PhD, Hobart, Tasmania, Australia
Richard E. Kanner, MD, Salt Lake City, Utah, USA
Hafsa Khaled, MD, Ksar Hellal, Tunisia
Jane Kirkby, PhD, London, UK
Jana Kivastik, MD, PhD, Tartu, Estonia
Dieter Köhler, MD, Kloster Grafschaft, Germany
Nino Künzli, MD, PhD, Basel, Switzerland
S.M. Lam, MD, Hong Kong, China
Arnulf Langhammer, MD, PhD, Levanger, Norway
Le Thi Tuyet Lan, MD, Ho Chi Min City, Vietnam
Arthur C.W. Lau, MBBS, FHKAM (Medicine), FCCP, Hong Kong, China

Mark L. Levy, MBChB, MRCGP, FRCGP, Kenton, UK
Carmen Lisboa, MD, Santiago, Chile
Sooky Lum, PhD, London, UK
Neil MacIntyre, MD, Durham NC, USA
Peter T. Macklem, BA MD CM FRCP FRSC, Doct Hon Causa Brussels & Athens, Montreal, Canada
Yves Martinet, MD, PhD, Nancy, France
Gail McAvay, PhD, New Haven, Connecticut
John McLachlan, MBChB (Cape Town), FCP(SA), FRACP, CRFS, Hamilton, New Zealand
Astri Medbø, A Spes GP, PhD, Tromsø, Norway
Robert B. Mellins MD, New York, NY, USA
Peter J.F.M. Merkus, MD, PhD, Nijmegen, the Netherlands
Albert Miller, MD, New York, NY, USA
Carl Mottram, RRT, RPFT, Rochester MN, USA
Pavlos Myrianthefs, MD, PhD, Kifissia, Greece
Jan Olofson, MD, PhD, R, Gothenburg, Sweden
Stanislaw Ostrowski MD, PhD, Lublin, Poland
Smita Pakhalé, MD, FRCPC, MSc (Epi & Biostat), Ottawa, ON, Canada
Riccardo Pellegrino, MD, Cuneo, Italy
Carlos A.C. Pereira, MD, São Paulo, Brazil
Thierry Perez, MD, Lille, France
Edward L. Petsonk, MD, Morgantown, WV, USA
Francesco Pistelli, MD, PhD, Pisa, Italy
Prasad KVV, MD, Hyderabad, India
Jeff Pray, RRT, RPFT, Minneapolis, MN, USA
Jeffrey J. Pretto, Doc Hlth Sc, Newcastle, NSW, Australia
Neil B. Pride, MD, London, UK
Chengli Que, MD. PhD Beijing, China
Sitarama Raju P., MD, Hyderabad, India
Richard G. Roberts, MD, JD, Madison, WI, USA
Nicolas Roche, MD, PhD, Paris, France
Leanne Rodwell, PhD, Brisbane, Australia
David Robiony-Rogers, MBA, CRFS, Wellington, Australia
Nicolas Roche, MD, Paris, France
Margaret Rosenfeld, MD, MPH, Seattle, WA, USA
Bart Rottier, MD, Groningen, the Netherlands
Sonia Rouatbi, MD, Sousse, Tunisia
Richard E.K. Russell, MD, PhD, London, UK
Maureen Rutten-van Mölken, PhD, Maastricht, the Netherlands
Paul D. Scanlon, MD, Rochester, MN, USA
Onno van Schayck, PhD, Maastricht, The Netherlands
Tjard Schermer, MD, PhD, Nijmegen, the Netherlands
Philippe Serrier, MD, Paris, France
Thomas Similowski, MD, PhD, Paris, France
Iain R. Small, MD, Aberdeen, UK
Henk Stam, PhD, Rotterdam, the Netherlands
Sanja Stanojevic, PhD, London, UK
Irene Steenbruggen, RRT, RPFT, Zwolle, the Netherlands
Paul S. Stephenson, MA, FRCGP, Haverhill, Suffolk, UK
Christian Straus, MD, PhD, Paris, France
James Sullivan, BA, RPFT, New York, NY, USA
Madhavi Sunitha, MBBS, Hyderabad, India
An De Sutter, MD, PhD, Ghent, Belgium
Gerhard W. Sybrecht MD, Homburg/Saar, Germany
Robin Taylor, MD, Dunedin, New Zealand
Frank Thien, MD, FRACP, Melbourne, Australia
Bruce R. Thompson, PhD, Melbourne, Australia
Waldemar Tomalak, MD, Rabka, Poland
Dominique Valeyre, MD, Bobigny, France
Peter H. Van Ness, PhD, MPH, New Haven, CT, USA
Jan Vandevoorde, MD, PhD, Brussels, Belgium
Daphna Vilozni, PhD, Tel Aviv, Israel
William M. Vollmer, PhD, Portland, OR, USA
Karlman Wasserman, MD, PhD, Torrance, California, USA
Chris van Weel, MD, PhD, Nijmegen, the Netherlands
Stephen N. West, M App Sci, Sydney Australia
Patrick White, Senior Lecturer, London, UK
Lisa Wilson, Respir Physiologist, Invercargill, New Zealand
Colin Wong, MD, Dunedin, New Zealand
E.F.M. Wouters, Maastricht, the Netherlands
Marc Zelter, MD, PhD, Paris, France
Jan Zieliński, MD, PhD, Warsaw, Poland

Publications implicitly or explicitly critical of the use of the fixed FEV_1/FVC ratio

1. Quanjer PH, Tammeling GJ, Cotes JE, *et al*. Lung volumes and forced ventilatory flows. *Eur Respir J* 1993; 6 suppl. 16: 5-40.
2. Falaschetti E, Laiho, Primatesta P, Purdon S. Prediction equations for normal and low lung function from the Health Survey for England. *Eur Respir J* 2004; 23: 456-463.
3. Stanojevic S, Wade A, Stocks J, *et al*. Reference ranges for spirometry across all ages. A new approach. *Am J Respir Crit Care Med* 2008; 177: 253–260.
4. http://www.spirxpert.com/GOLD.html, downloading the software gives access to over 80 sets of prediction equations and over 50,000 data demonstrating how the GOLD criteria lead to under diagnosis in young subjects and over diagnosis in those over 50 yr.
5. http://www.spirxpert.com/controversies/controversy.html explains why the use of a fixed ratio is flawed.
6. Stanojevic S, Wade A, Stocks J. Reference values for lung function: past, present and future. *Eur Respir J* 2010; 36: 12-19.
7. Hardie JA, Buist AS, Vollmer WM *et al*. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. *Eur Respir J* 2002; 20: 1117-1120
8. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. *Eur Respir J* 2003; 22: 268-273.
9. Roberts SD, Farber MO, Knox KS, *et al.* FEV_1/FVC ratio of 70% misclassifies patients with obstruction at the extremes of age. *Chest* 2006; 130: 200-206.
10. Aggarwal AN, Gupta D, Behera D, Jindal SK. Comparison of fixed percentage method and lower confidence limits for defining limits of normality for interpretation of spirometry. *Respir Care* 2006; 51: 737–743.
11. Miller MR, Steenbruggen I, Quanjer PH, *et al.* Defining the lower limit of normal for FEV_1/ FVC. Letter to the Editor. *Am J Resp Crit Care Med* 2007; 176: 101-102
12. Miller MR. What defines abnormal lung function? Letter to the Editor. *Thorax* 2007; 62: 1107.
13. Petsonk EL, Hnizdo E, Attfield M. Definition of COPD GOLD stage I. Letter to the Editor. *Thorax* 2007; 62: 1107-1108.
14. Medbø A, Melbye H. Lung function testing in the elderly - Can we still use the FEV_1/FVC <70% as a criterion for

COPD? *Respir Med* 2007; 101: 1097-1105
15. Shirtcliffe P, Weatherall M, Marsh S, *et al*. COPD prevalence in a random population survey: a matter of definition. *Eur Respir J* 2007; 30: 232–239.
16. Vollmer WM, Gíslason B, Burney P, *et al*. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. *Eur Respir J* 2009; 34: 588–597.
17. Miller MR, Pedersen OF, Pellegrino R, Brusasco V. Debating the definition of airflow obstruction: time to move on? Editorial. *Eur Respir J* 2009; 34: 527–528.
18. Swanney MP, Ruppel G, Enright PL, *et al*. Using the lower limit of normal for the FEV_1/FVC ratio reduces the misclassification of airway obstruction. *Thorax* 2008; 63; 1046-1051.
19. Olofson J, Bake B, Tengelin MN, Houltz B. COPD 'diagnosis' based on spirometric reference equations. *Clin Respir J* 2008; 2: 214–219.
20. Ko FWS, Woo J, Tam W, C. Lai KW, Ngai J, Kwok T, Hui DSC. Prevalence and risk factors of airflow obstruction in an elderly Chinese population. *Eur Respir J* 2008; 32:1472-1478
21. Lau AC, Ip MS, Lai CK, Choo KL, Tang KS, Yam LY, Chan-Yeung M. Variability of the prevalence of undiagnosed airflow obstruction in smokers using different diagnostic criteria. *Chest* 2008; 133 (1): 42-48.
22. Schermer TR, Smeele IJ, Thoonen BP, *et al*. Current clinical guideline definitions for airflow obstruction leads to substantial overdiagnosis of COPD in primary care. *Eur Resp J* 2008;32(4):945-952.
23. Levy ML, Quanjer PH, Booker R, Cooper BG, Holmes S, Small I. Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations. *Prim Care Resp J* 2009; 18(3): 130-147.
24. Schermer TRJ, Quanjer PH. COPD screening in primary care: Who is sick? *Prim Care Respir J* 2007;16: 49-53.
25. Pérez-Padilla R, Hallal PC, Vázquez-García JC, *et al*. Impact of bronchodilator Use on the prevalence of COPD in population-based samples. *COPD: J Chronic Obstructive Pulmonary Disease* 2007; 4: 113–120.
26. Vaz Fragoso CA, Concato J, McAvay G, *et al*. The ratio of forced expiratory volume in 1-second to forced vital capacity as a basis for establishing chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010; 181: 446-451.
27. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80 percent of predicted and 5 fixed thresholds misclassifies over 20% of patients. Published online before print June 3, 2010, doi: 10.1378/chest.10-0189 *chest.10-0189.*
28. Enright PL. GOLD stage I is not a COPD risk factor. Letter to the Editor. *Thorax* 2007; 62: 1107.
29. Miller MR, Pincock AC. Predicted values: how should we use them? *Thorax* 1988; 43: 265-267.
30. ATS Statement. Lung function testing: selection of reference values and interpretative strategies. *Am Rev Respir Dis* 1991; 144: 1202-1218.
31. Pellegrino R, Viegi G, Brusasco V, *et al*. Interpretative strategies for lung function tests. Series "ATS/ERS Task Force: Standardisation of Lung Function Testing". *Eur Respir J* 2005; 26: 948-968.
32. Townsend MC. Conflicting definitions of airways obstruction: drawing the line between normal and abnormal. Editorial. *Chest* 2007; 131: 335-336.
33. Kerstjens HAM. The GOLD classification has not advanced understanding of COPD. Pro/Con Editorial. *Am J Respir Crit Care Med* 2004; 170: 212-213.
34. Enright P, Quanjer P. Don't diagnose mild COPD without confirming airway obstruction after an inhaled bronchodilator. Editorial. *COPD* 2007; 4: 89-90.
35. Culver BH. Interpretation of spirometry: we can do better than the GOLD standard. Editorial. *Respir Care* 2006; 51: 719-721.
36. Wilt T, Niewoehner DE, Kim C-B, *et al*. 2005. Use of spirometry for case finding, diagnosis, and management of Chronic Obstructive Pulmonary Disease (COPD). Evidence Report/Technology Assessment No. 121 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. 290-02-0009.) AHRQ Publication No. 05-E017-2. Rockville, MD. Agency for Healthcare Research and Quality.
37. Hnizdo E, Glindmeyer HW, Petsonk EL, *et al.* Case definitions for chronic obstructive pulmonary disease. *COPD* 2006; 3: 1-6.
38. Hansen JE, Sun X-G, Wasserman K. Spirometric criteria for airway obstruction. Use percentage of FEV_1/FVC ratio below the fifth percentile, not <70%. *Chest* 2007; 131: 349-355.
39. Cerveri I, Corsico AG, Accordini S, *et al*. Underestimation of airflow obstruction among young adults using FEV_1/FVC <70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. *Thorax* 2008; 63; 1040-1045.
40. Cerveri I, Corsico AG, Accordini S, *et al*. What defines airflow obstruction in asthma? *Eur Respir J* 2009; 34: 568–573.